Diabetic Neuropathy: Function-Structure of Corneal Nerves to Assess Injury-Repair
糖尿病神经病变:角膜神经的功能结构评估损伤修复
基本信息
- 批准号:8998985
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-01-01 至 2016-12-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAffectAmputationAngiotensin IIAngiotensin ReceptorAngiotensin-Converting Enzyme InhibitorsAnimal ModelAnimalsBiological PreservationBlood VesselsChronicClinicalClinical TrialsComplicationConfocal MicroscopyCorneaDevelopmentDiabetes MellitusDiabetic NeuropathiesDiagnosisDisease ProgressionDoseEarly DiagnosisEpidemicEsthesiaFamilyFatty acid glycerol estersFiberFilamentFunctional disorderGoalsGossypiumHealthcare SystemsHumanImageImmuneImpairmentInflammationLongitudinal StudiesMeasurementMeasuresMediatingMethodologyMethodsModalityModelingMonitorMorphologyMotorNeprilysinNerveNerve EndingsNerve FibersNerve RegenerationNeural ConductionNeuropathyNociceptionNon-Insulin-Dependent Diabetes MellitusOutcomeOutcome MeasureOutcome StudyOxidative StressPatientsPeptidesPeripheralPeripheral NervesPeripheral Nervous System DiseasesPharmaceutical PreparationsPhasePhenolsulfonphthaleinPopulationPrevention therapyPreventive InterventionProductionProprioceptionProtease InhibitorProtocols documentationQuality of lifeRehabilitation therapyRelaxationResearch DesignSafetySensorySkinSkin UlcerStreptozocinStructureSurrogate MarkersTechniquesTestingTherapeuticTherapeutic AgentsTherapeutic InterventionTimeTissuesTranslationsTreatment ProtocolsTrigeminal SystemVascular blood supplyVeteransVideo Microscopyafferent nervearterioleautonomic nervebaseciliary arterycorneal repairdensitydiabeticdiabetic patientdiabetic ratearly onseteffective therapyefficacy testingfeedingimprovedinjury and repairmortalitynerve supplynovel therapeuticspre-clinical trialpreclinical efficacypreclinical studypreventtargeted treatmenttooltreatment responsetreatment strategy
项目摘要
DESCRIPTION (provided by applicant):
This proposal aims to test two promising new treatments for diabetic neuropathy, Ilepatril and LCZ696.
Each of these drugs acts through two mechanisms proposed to preserve peripheral nerves in diabetes: 1) to reduce the effect of angiotensin II on immune-mediated nerve damage and to reduce its effect on vessels supplying peripheral nerves, acting to improve their blood supply, and 2) to inhibit neutral endopeptidase, which will make neuro- and vaso-active peptides more available at nerve endings to maintain vascular and nerve integrity and function. This proposal will also validate the use of corneal nerve morphology and sensory function as valid early small fiber markers of diabetic peripheral neuropathy. The structure and function of corneal nerves are proposed as surrogates for detecting diabetic neuropathy early in humans and animal models and for use as outcome measures for the new treatments proposed. Our long term objective is to conduct pre-clinical trials with the intent of identifying new effective treatments
for diabetic neuropathy and to advance this treatment to clinical trials using corneal nerve structure and
sensory function as outcome measures. Progress toward this goal has been hampered by the lack of a
sensitive and reliable method for diagnosing and monitoring peripheral neuropathy. Recently, corneal confocal microscopy has shown promise as a non-invasive method for quantifying the damage and repair of corneal sensory nerves and to serve as a surrogate marker for diabetic neuropathy. Preliminary studies of corneal nerves in human diabetic patients have been promising, but studies in animal models characterizing diabetic corneal nerve damage by monitoring their structure and sensory function over time have yet to be performed.
The immediate goals of this application are to examine the development, progression and repair of corneal neuropathy in animal models of type 2 diabetes. This will be accomplished by investigating the structural integrity of corneal nerves using confocal microscopy and their function by using a Cochet-Bonnet filament esthesiometer. In addition to corneal sensation, rate of tear production will also be monitored using Zone-Quick cotton threads (similar to a Schirmer's test in humans). Corneal structural and functional results will be compared to standard endpoints used to identify diabetic peripheral neuropathy, including motor and sensory nerve conduction velocity, thermal nociception and intraepidermal nerve fiber density in the hindpaw. After validating corneal nerves as a surrogate marker for diabetic neuropathy, we will test the efficacy of two promising new treatment approaches on diabetes-induced corneal nerve damage and function. The treatment hypothesis to be examined is whether diabetic corneal nerve damage is caused to a large extent by modifiable factors targeted by treatment with Ilepatril and/or LCZ696.
The first phase of the study will address the hypothesis that type 2 diabetes causes an early and
progressive loss of corneal nerves, reduces corneal sensitivity and decreases vascular relaxation in the
posterior ciliary artery, which supplies the orbital portion of the trigeminal corneal nerves. It i hypothesized that corneal nerve damage and dysfunction will precede peripheral diabetic neuropathy. A longitudinal study in high fat fed/low dose streptozotocin diabetic rats, an accepted model of type 2 diabetes, will test this hypothesis. These studies will provide an understanding of the progression of diabetic nerve damage. The second phase of the study will address the hypothesis that corneal nerve fiber loss, corneal dysfunction and impaired vascular reactivity of the posterior ciliary artery can be rescued by treating type 2 diabetic rats with Ilepatril and/or LCZ696. Results from these studies will determine whether prevention and intervention therapies can improve diabetes-induced corneal nerve impairment. These studies will provide a basis for the use of non-invasive assessment of structure and function of corneal nerves as a clinical tool for assessing diabetic peripheral neuropathy and its treatment in human clinical trials.
DESCRIPTION (provided by applicant):
This proposal aims to test two promising new treatments for diabetic neuropathy, Ilepatril and LCZ696.
Each of these drugs acts through two mechanisms proposed to preserve peripheral nerves in diabetes: 1) to reduce the effect of angiotensin II on immune-mediated nerve damage and to reduce its effect on vessels supplying peripheral nerves, acting to improve their blood supply, and 2) to inhibit neutral endopeptidase, which will make neuro- and vaso-active peptides more available at nerve endings to maintain vascular and nerve integrity and function. This proposal will also validate the use of corneal nerve morphology and sensory function as valid early small fiber markers of diabetic peripheral neuropathy. The structure and function of corneal nerves are proposed as surrogates for detecting diabetic neuropathy early in humans and animal models and for use as outcome measures for the new treatments proposed. Our long term objective is to conduct pre-clinical trials with the intent of identifying new effective treatments
for diabetic neuropathy and to advance this treatment to clinical trials using corneal nerve structure and
sensory function as outcome measures. Progress toward this goal has been hampered by the lack of a
sensitive and reliable method for diagnosing and monitoring peripheral neuropathy. Recently, corneal confocal microscopy has shown promise as a non-invasive method for quantifying the damage and repair of corneal sensory nerves and to serve as a surrogate marker for diabetic neuropathy. Preliminary studies of corneal nerves in human diabetic patients have been promising, but studies in animal models characterizing diabetic corneal nerve damage by monitoring their structure and sensory function over time have yet to be performed.
The immediate goals of this application are to examine the development, progression and repair of corneal neuropathy in animal models of type 2 diabetes. This will be accomplished by investigating the structural integrity of corneal nerves using confocal microscopy and their function by using a Cochet-Bonnet filament esthesiometer. In addition to corneal sensation, rate of tear production will also be monitored using Zone-Quick cotton threads (similar to a Schirmer's test in humans). Corneal structural and functional results will be compared to standard endpoints used to identify diabetic peripheral neuropathy, including motor and sensory nerve conduction velocity, thermal nociception and intraepidermal nerve fiber density in the hindpaw. After validating corneal nerves as a surrogate marker for diabetic neuropathy, we will test the efficacy of two promising new treatment approaches on diabetes-induced corneal nerve damage and function. The treatment hypothesis to be examined is whether diabetic corneal nerve damage is caused to a large extent by modifiable factors targeted by treatment with Ilepatril and/or LCZ696.
The first phase of the study will address the hypothesis that type 2 diabetes causes an early and
progressive loss of corneal nerves, reduces corneal sensitivity and decreases vascular relaxation in the
posterior ciliary artery, which supplies the orbital portion of the trigeminal corneal nerves. It i hypothesized that corneal nerve damage and dysfunction will precede peripheral diabetic neuropathy. A longitudinal study in high fat fed/low dose streptozotocin diabetic rats, an accepted model of type 2 diabetes, will test this hypothesis. These studies will provide an understanding of the progression of diabetic nerve damage. The second phase of the study will address the hypothesis that corneal nerve fiber loss, corneal dysfunction and impaired vascular reactivity of the posterior ciliary artery can be rescued by treating type 2 diabetic rats with Ilepatril and/or LCZ696. Results from these studies will determine whether prevention and intervention therapies can improve diabetes-induced corneal nerve impairment. These studies will provide a basis for the use of non-invasive assessment of structure and function of corneal nerves as a clinical tool for assessing diabetic peripheral neuropathy and its treatment in human clinical trials.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RANDY H. KARDON其他文献
RANDY H. KARDON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RANDY H. KARDON', 18)}}的其他基金
Center for the Prevention and Treatment of Visual Loss
视力丧失预防和治疗中心
- 批准号:
10275482 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Early Visual Biomarkers of Relapse and Rehabilitation in Multiple Sclerosis
多发性硬化症复发和康复的早期视觉生物标志物
- 批准号:
10411975 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Early Visual Biomarkers of Relapse and Rehabilitation in Multiple Sclerosis
多发性硬化症复发和康复的早期视觉生物标志物
- 批准号:
10189737 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Center for the Prevention and Treatment of Visual Loss
视力丧失预防和治疗中心
- 批准号:
10663778 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Diabetic Neuropathy: Function-Structure of Corneal Nerves to Assess Injury-Repair
糖尿病神经病变:角膜神经的功能结构评估损伤修复
- 批准号:
9293574 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Diabetic Neuropathy: Function-Structure of Corneal Nerves to Assess Injury-Repair
糖尿病神经病变:角膜神经的功能结构评估损伤修复
- 批准号:
10339313 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Diabetic Neuropathy: Function-Structure of Corneal Nerves to Assess Injury-Repair
糖尿病神经病变:角膜神经的功能结构评估损伤修复
- 批准号:
10631891 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Cholinergic Drugs For Reversal Of Visual Deficits In Glaucoma
用于逆转青光眼视力缺陷的胆碱能药物
- 批准号:
8857398 - 财政年份:2010
- 资助金额:
-- - 项目类别:
Cholinergic Drugs For Reversal Of Visual Deficits In Glaucoma
用于逆转青光眼视力缺陷的胆碱能药物
- 批准号:
8466759 - 财政年份:2010
- 资助金额:
-- - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists